GlassScriptPhysician profile
Monte L Cordray
NPI 1134236557
$867.79
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $163 · 2021: $321 · 2022: $23.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $245.72 | 2019-2022 | |
| Astellas Pharma US INC | $211.59 | 2019-2021 | |
| Pfizer INC. | $90.72 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $44.28 | 2021 | |
| Neotract INC. | $40.21 | 2019 | |
| Boston Scientific Corporation | $30.29 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $29.26 | 2020 | |
| Myovant Sciences INC. | $28.53 | 2021 | |
| Coloplast Corp | $24.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $22.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.64 | 2019 | |
| Axonics, INC. | $16.74 | 2021 | |
| Janssen Scientific Affairs, LLC | $15.66 | 2020 | |
| Convatec INC. | $14.83 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.35 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $11.47 | 2021 | |
| Abbvie INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Cordray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.